The latest treatment of colorectal cancer - a review paper
DOI:
https://doi.org/10.12775/QS.2024.26.54871Keywords
colorectal cancer, immunotherapy, oncology, crc, latest treatment of colorectal cancer, nutrition in colorectal cancerAbstract
The review article discusses the latest therapeutic approaches in the treatment of colorectal cancer (CRC), with a particular focus on metastatic disease. Despite advancements in standard treatments such as surgery, chemotherapy, and targeted therapies, the prognosis for patients with metastatic CRC remains poor, with five-year survival rates still low. The article examines the potential of immunotherapy, including PD-1 inhibitors like dostarlimab, which have shown promising results in treating selected patient groups. Additionally, the role of the ketogenic diet and probiotics as supportive strategies in CRC treatment is discussed, highlighting their potential to influence cancer metabolism and improve therapeutic outcomes. The article also addresses the development of nanotechnology-based therapies, such as PEGylated PLGA nanoparticles and sphingomyelin nanosystems, which may enhance drug delivery precision, thereby improving treatment efficacy and minimizing side effects. The conclusion emphasizes the need for further research into these innovative therapies and their integration with existing treatment protocols to improve survival and quality of life for CRC patients.
References
World Health Organisation (WHO). Colorectal cancer [Internet]. 2023 [Accessed 4 September 2024]. Available online: https://www.who.int/news-room/fact-sheets/detail/colorectal-cancer
Krajowy Rejestr Nowotworów. Krajowy Rejestr Nowotworów. 2021 [Accessed 4 September 2024]. Nowotwory złośliwe w Polsce. Available online: http://onkologia.org.pl/pl/epidemiologia/nowotwory-zlosliwe-w-polsce
Potemski P, Bujko K, Rutkowski A, Krzakowski M. Wytyczne postępowania diagnostyczno-terapeutycznego u chorych na raka okrężnicy (C18) i zagięcia esiczo-odbytniczego (C19). Oncol Clin Pract. 17 August 2020;16(4):183–93.
Kalyan A, Kircher S, Shah H, Mulcahy M, Benson A. Updates on immunotherapy for colorectal cancer. J Gastrointest Oncol. February 2018;9(1):160–9.
Cercek A, Lumish M, Sinopoli J, Weiss J, Shia J, Lamendola-Essel M, i in. PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer. N Engl J Med. 23 June 2022;386(25):2363–76.
Lenz HJ, Van Cutsem E, Luisa Limon M, Wong KYM, Hendlisz A, Aglietta M, i in. First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study. JCO. 10 January 2022;40(2):161–70.
Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, i in. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 25 June 2015;372(26):2509–20.
Kim J, Lee HK. Potential Role of the Gut Microbiome In Colorectal Cancer Progression. Front Immunol. 2021;12:807648.
Grivennikov SI. Inflammation and colorectal cancer: colitis-associated neoplasia. Semin Immunopathol. March 2013;35(2):229–44.
Cheng Y, Ling Z, Li L. The Intestinal Microbiota and Colorectal Cancer. Front Immunol. 2020;11:615056.
Yang Y, Weng W, Peng J, Hong L, Yang L, Toiyama Y, i in. Fusobacterium nucleatum Increases Proliferation of Colorectal Cancer Cells and Tumor Development in Mice by Activating Toll-Like Receptor 4 Signaling to Nuclear Factor-κB, and Up-regulating Expression of MicroRNA-21. Gastroenterology. March 2017;152(4):851-866.e24.
Chung L, Orberg ET, Geis AL, Chan JL, Fu K, DeStefano Shields CE, i in. Bacteroides fragilis Toxin Coordinates a Pro-carcinogenic Inflammatory Cascade via Targeting of Colonic Epithelial Cells. Cell Host Microbe. 14 March 2018;23(3):421.
Rubinstein MR, Wang X, Liu W, Hao Y, Cai G, Han YW. Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/β-catenin signaling via its FadA adhesin. Cell Host Microbe. 14 August 2013;14(2):195–206.
Long X, Wong CC, Tong L, Chu ESH, Ho Szeto C, Go MYY, i in. Peptostreptococcus anaerobius promotes colorectal carcinogenesis and modulates tumour immunity. Nat Microbiol. December 2019;4(12):2319–30.
Dai Z, Coker OO, Nakatsu G, Wu WKK, Zhao L, Chen Z, i in. Multi-cohort analysis of colorectal cancer metagenome identified altered bacteria across populations and universal bacterial markers. Microbiome. 11 April 2018;6(1):70.
Fong W, Li Q, Yu J. Gut microbiota modulation: a novel strategy for prevention and treatment of colorectal cancer. Oncogene. June 2020;39(26):4925–43.
Lewandowska A, Religioni U, Czerw A, Deptała A, Karakiewicz B, Partyka O, i in. Nutritional Treatment of Patients with Colorectal Cancer. Int J Environ Res Public Health. 4 czerwiec 2022;19(11):6881.
Ambalam P, Raman M, Purama RK, Doble M. Probiotics, prebiotics and colorectal cancer prevention. Best Pract Res Clin Gastroenterol. February 2016;30(1):119–31.
Li Q, Liu D, Liang M, Zhu Y, Yousaf M, Wu Y. Mechanism of probiotics in the intervention of colorectal cancer: a review. World J Microbiol Biotechnol. 20 August 2024;40(10):306.
Weng W, Goel A. Curcumin and colorectal cancer: An update and current perspective on this natural medicine. Semin Cancer Biol. May 2022;80:73–86.
Tamraz M, Al Ghossaini N, Temraz S. The Ketogenic Diet in Colorectal Cancer: A Means to an End. Int J Mol Sci. 12 February 2023;24(4):3683.
Shin AE, Giancotti FG, Rustgi AK. Metastatic colorectal cancer: mechanisms and emerging therapeutics. Trends Pharmacol Sci. April 2023;44(4):222–36.
Nagao K, Koshino A, Sugimura-Nagata A, Nagano A, Komura M, Ueki A, i in. The Complete Loss of p53 Expression Uniquely Predicts Worse Prognosis in Colorectal Cancer. Int J Mol Sci. 17 March 2022;23(6):3252.
Michel M, Kaps L, Maderer A, Galle PR, Moehler M. The Role of p53 Dysfunction in Colorectal Cancer and Its Implication for Therapy. Cancers (Basel). 11 May 2021;13(10):2296.
Haggag YA, Osman MA, El-Gizawy SA, Goda AE, Shamloula MM, Faheem AM, i in. Polymeric nano-encapsulation of 5-fluorouracil enhances anti-cancer activity and ameliorates side effects in solid Ehrlich Carcinoma-bearing mice. Biomed Pharmacother. wrzesień 2018;105:215–24.
Bouzo BL, Lores S, Jatal R, Alijas S, Alonso MJ, Conejos-Sánchez I, i in. Sphingomyelin nanosystems loaded with uroguanylin and etoposide for treating metastatic colorectal cancer. Sci Rep. 26 August 2021;11(1):17213.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Anna Wojtkiewicz, Magda Piekarska, Zuzanna Kudas, Krzysztof Szerej, Mateusz Górka, Weronika Stec
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 158
Number of citations: 0
